FACTSHEET HUMAN EXPERIMENTATION - 166 (SFS9.001)

Project Name: Boston Project

Date Started: 10/53
Date Terminated: 10/57

Institution:
Funding Source(s): AEC

Identification: AT(30-1)1093
Project Duration:
Principal Investigator(s): W.H. Sweet (Mass. Gen. Hospital); A.J. Luessenhop (Mass. Gen. Hospital); E.G. Struxness (ORNL)

Responsible Government Official(s): John C. Bugher, M.D.
Charles L. Dunham, M.D.

Objective(s) of Project: Derivation of tolerance dose of hexavalent uranium for man and procurement of data on the distribution and excretion of this ion to aid in evaluating exposures in uranium processing and fabrication plants and as an initial step in application of U-235 induced fission in treatment of brain tumors.

Short Description: About 12 tumor patients were selected for the study. Uranium in the nitrate and/or citrate form was intravenously injected. Blood, urine, and feces samples were collected. Tissue samples were obtained at biopsy and autospy. See Ref. below for the clinical procedures.

Follow-up Data: All subjects were terminal brain tumor patients who expired within less than one and one-half years after entering study.

References:

1. E.G. Struxness, A.J. Luessenhop, S.R. Bernard, and J.C. Gallimore, "The Distribution and Excretion of Hexavalent Uranium in Man," Proceedings of the International Conference on the Peaceful Uses of Atomic Energy, Geneva, Aug. 8-20, 1955.

2. S.R. Bernard, "Maximum Permissible Amount of Natural Uranium in the Body, Air, and Drinking Water Based on Human Experimental Data," Health Physics. 1 288 (1958).

3. A.J. Luessenhop, J.C. Gallimore, W.H. Sweet, E.G. Struxness, and J. Robinson, "The Toxicity in Man of Hexavalent Uranium following Intraveneous Administration," Am. J. Roentgenol. 79, 83 (1958).

1061318

DOE/HQ

ISH.166 (cont'd)

Attachment(s): Copies of above references are attached.